Henry E. Chang is Executive Director of the Fatty Liver Foundation, a U.S.-based nonprofit organization established in 2017 dedicated to improving early detection, education, and care for individuals affected by steatotic liver disease. He serves as Program Director of the Dr. Stephen A. Harrison Patient Advocacy Fellowship and is Co-Chair of the Patient Engagement in Drug Development Leading Through Example (PEDDLE) working group of the Liver Forum under the Forum for Collaborative Research, UC Berkeley School of Public Health. Mr. Chang attended the graduate program in Molecular Biology at the University of California, Los Angeles (UCLA) and completed a clinical research fellowship in infectious disease at Cedars-Sinai Medical Center, UCLA School of Medicine. He has served on the Practice Guidelines Committee of the American Association for the Study of Liver Diseases (AASLD) and on advisory boards for the NYC Department of Health and Mental Hygiene's Hepatitis B Coalition and Hepatitis C Task Force. His research includes population-based studies on the screening and detection of MASLD/MASH, and he has been an active contributor to advancing patient-centered approaches to steatotic liver disease care in the U.S. Earlier in his career, Mr. Chang served as Executive Director of Global Immunity at the AIDS Healthcare Foundation, where he helped establish HIV treatment programs in 28 low- and middle-income countries, as Senior Director of Scientific and Community Relations at DuPont Pharmaceuticals, as Executive Director of Médecins du Monde (Doctors of the World-USA), as Vice President of the Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria, and was a co-founder of the ACT UP/Los Angeles Treatment and Data Committee.